References
- Van Wegberg AMJ, MacDonald A, Ahring K, et al. The complete European guidelines on phenylketonuria: diagnosis and treatment. Orphanet J Rare Dis. 2017;12:162.
- Blau N, van Spronsen FJ, Levy HL. Phenylketonuria. Lancet. 2010;376:1417–1427.
- Loeber JG. Neonatal screening in Europe; the situation in 2004. J Inherit Metab Dis. 2007;30:430–438.
- El-Metwally A, Yousef Al-Ahaidib L, Ayman Sunqurah A, et al. The prevalence of phenylketonuria in Arab Countries, Turkey, and Iran: a systematic review. Biomed Res Int. 2018;2018:1.
- Kääriäinen H, Muilu J, Perola M, et al. Genetics in an isolated population like Finland: a different basis for genomic medicine? J Community Genet. 2017;8:319–326.
- Desviat LR, Pérez B, Gámez A, et al. Genetic and phenotypic aspects of phenylalanine hydroxylase deficiency in Spain: molecular survey by regions. Eur J Hum Genet. 1999;7:386–392.
- Vicente E, Casas L, Ardanaz E. Origin of newborn screening programs and their beginnings in Spain [Origen de los programas de cribado neonatal y sus inicios en España]. An Sist Sanit Navar. 2017;40:131–140.
- van Spronsen FJ. Phenylketonuria: a 21st century perspective. Nat Rev Endocrinol. 2010;6:509–514.
- Lichter-Konecki U, Vockley J. Phenylketonuria: current treatments and future developments. Drugs. 2019;79:495–500.
- Brosco JP, Sanders LM, Seider MI, et al. Adverse medical outcomes of early newborn screening programs for phenylketonuria. Pediatrics. 2008;122:192–197.
- Darbà J, Ascanio M. Admissions and cost of hospitalisation of phenylketonuria: Spanish claims database analysis. Clin Drug Investig. 2019;39:379.
- Public program of data analysis for research and innovation in health in Catalonia [Programa públic d'analítica de dades per a la recerca i la innovació en salut a Catalunya]. Health evaluation and quality agency of Catalonia. Health Department. Generalitat de Catalunya. http://aquas.gencat.cat/ca/detall/article/padris [Accessed April 2019].
- Monterde D, Vela E, Clèries M, et al. Adjusted morbidity groups: a new multiple morbidity measurement of use in Primary Care. Atención Primaria. 2016;48:674–682.
- Catalonia. SLT/353/2013, 13th of February, revision of public prices for sanitary services offered by the Catalan Institute of Health [revisió de preus públics corresponents als serveis sanitaris que presta l’Institut Català de la Salut]. (DOGC number 6326 - 1.3.2013).
- Catalonia. SLT/235/2013, 9th of September, that establishes the values of payment units for the services supplied by social health centres in 2013 [per la qual s'estableixen per a l'any 2013 els valors de les unitats de pagament per a la contraprestació dels serveis duts a terme pels centres sociosanitaris]. (DOGC number 6478 - 11.10.2013).
- Borkan J, Eaton CB, Novillo-Ortiz D, et al. Renewing primary care: lessons learned from the Spanish health care system. Health Aff (Millwood). 2010;29:1432–1441.
- Report of the Project of Stratification of the Population in GMA groups in the National Health System (2014–2016). [Informe del proyecto de Estratificación de la Población por Grupos de Morbilidad Ajustados (GMA) en el Sistema Nacional de Salud (2014–2016)]. Spanish Ministry of Health; 2018.
- Burton BK, Jones KB, Cederbaum S, et al. Prevalence of comorbid conditions among adult patients diagnosed with phenylketonuria. Mol Genet Metab. 2018;125:228–234.
- Alfheeaid H, Gerasimidis K, Năstase AM, et al. Impact of phenylketonuria type meal on appetite, thermic effect of feeding and postprandial fat oxidation. Clin Nutr. 2018;37:851–857.
- Bilder DA, Kobori JA, Cohen-Pfeffer JL, et al. Neuropsychiatric comorbidities in adults with phenylketonuria: a retrospective cohort study. Mol Genet Metab. 2017;121:1–8.
- Payne RA, Abel GA, Guthrie B, et al. The effect of physical multimorbidity, mental health conditions and socioeconomic deprivation on unplanned admissions to hospital: a retrospective cohort study. CMAJ. 2013;185:E221–E228.
- Tinetti ME, Fried TR, Boyd CM. Designing health care for the most common chronic condition—multimorbidity. JAMA. 2012;307:2493–2494.
- MacDonald A, Smith TA, de Silva S, et al. The personal burden for caregivers of children with phenylketonuria: a cross-sectional study investigating time burden and costs in the UK. Mol Genet Metab Rep. 2016;9:1–5.
- Wang L, Zou H, Ye F, et al. Household financial burden of phenylketonuria and its impact on treatment in China: a cross-sectional study. J Inherit Metab Dis. 2017;40:369–376.
- Berry SA, Brown C, Grant M, et al. Newborn screening 50 years later: access issues faced by adults with PKU. Genet Med. 2013;15:591–599.